The megakaryocyte is a bone marrow cell responsible for the production of blood platelets necessary for normal blood clotting. Megakaryocytes normally account for 1 out of 10,000 bone marrow cells but can increase in number nearly 10-fold in certain diseases.
In general, megakaryocytes are 10 to 15 times larger than a typical red blood cell, averaging 50-100 μm in diameter. During its maturation, the megakaryocyte grows in size and replicates its DNA without cytokinesis
. As a result, the nucleus of the megakaryocyte can become very large and lobulated, which, under a light microscope, can give the false impression that there are several nuclei. In some cases, the nucleus may contain up to 64N DNA, or 32 copies of the normal complement of DNA in a human cell.
The cytoplasm, just as the platelets that bud off from it, contains α-granula and dense bodies.
Megakaryocytes are derived from hematopoietic stem cell precursor cells in the bone marrow. These pluripotent stem cells live in the marrow sinusoids and are capable of producing all types of blood cells depending on the signals they receive. The primary signal for megakaryocyte production is thrombopoietin or TPO. TPO is necessary for inducing differentiation of progenitor cells in the bone marrow towards a final megakaryocyte phenotype. Other molecular signals for megakaryocyte differentiation include GM-CSF, IL-3, IL-6, IL-11, and erythropoietin. The megakaryocyte develops through the following lineage:
CFU-Me (pluripotential hemopoietic stem cell or hemocytoblast) -> megakaryoblast -> promegakaryocyte -> megakaryocyte.
The cell eventually reaches megakaryoblast stage and loses its ability to divide. However, it is still able to replicate its DNA and continue development, becoming polyploid. The cytoplasm continues to expand and the DNA complement can increase up to 64N.
Once the cell has completed differentiation and become a mature megakaryocyte, it begins the process of producing platelets. Thrombopoietin
plays a role in inducing the megakaryocyte to form small proto-platelet processes. Platelets are held within these internal membranes within the cytoplasm of megakaryocytes. There are two proposed mechanisms for platelet release. In one scenario, these proto-platelet processes break up explosively to become platelets. Alternatively, the cell may form platelet ribbons into blood vessels. The ribbons are formed via pseudopodia
and they are able to continuously emit platelets into circulation. In either scenario, each of these proto-platelet processes can give rise to 2000-5000 new platelets upon breakup. Overall, 2/3 of these newly-produced platelets will remain in circulation while 1/3 will be sequestered by the spleen.
After budding off platelets, what remains is mainly the cell nucleus. This crosses the bone marrow barrier to the blood and is consumed in the lung by alveolar macrophages.
Effects of cytokines
are signals used in the immune system
for intercellular communication. There are many cytokines
which affect megakaryocytes. Certain cytokines such as IL-3
, and thrombopoietin
all stimulate the maturation of megakaryocytic progenitor cells. Other signals such as PF4
, and CCL5
inhibit platelet formation.
Thrombopoietin (TPO) is a 353-amino acid protein located on chromosome
3p27. TPO is primarily synthesized in the liver but can be made by kidneys, testes, brain, and even bone marrow stromal cells. It has high homology with erythropoietin
. It is necessary but not required for the formation of platelets. Mice lacking TPO or the TPO receptor (Mpl) have a 90% reduction in circulating platelet number, although the platelets are normal in morphology and function.
Disorders involving megakaryocytes
Megakaryocytes are directly responsible for producing platelets which are needed for the formation of a thrombus
, or blood clot. There are several diseases which are directly attributable to abnormal megakaryocyte function or abnormal platelet function.
(ET) is a disorder characterized by extremely high numbers of circulating platelets. The disease occurs in 1-2 per 100,000 people. The current WHO requirements for diagnosis include > 600,000 platelets/μL of blood (normal 150,000-400,000) and a bone marrow
biopsy. Some of the consequences of having such high numbers of platelets include thrombosis
or clots throughout the body. Thrombi form more frequently in arteries than veins. Ironically, having platelet counts above 1,000,000 platelets/μL can lead to hemorrhagic
events. Recent evidence suggests that the majority of ET cases are due to a mutation in the JAK2
protein, a member of the JAK
pathway. Evidence suggests this mutation renders the megakaryocyte hypersensitive to thrombopoietin and causes clonal proliferation of megakaryocytes. There is a significant risk of transformation to leukemia
with this disorder. The primary treatment consists of anegrelide
to lower platelet levels.
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia
(CAMT) is a rare inherited
disorder. The primary manifestations are thrombocytopenia
, or low numbers of platelets and megakaryocytes. There is an absence of megakaryocytes in the bone marrow with no associated physical abnormalities. The cause for this disorder appears to be a mutation in the gene for the TPO receptor, c-mpl
, despite high levels of serum TPO. In addition, there may be abnormalities with the central nervous system
including the cerebrum
which could cause symptoms. The primary treatment for CAMT is bone marrow transplantation
Bone Marrow/Stem Cell Transplant is the only thing that ultimately cures this genetic disease. Frequent platelet transfusions are required to keep the patient from bleeding to death until transplant is done, although this is not always the case.
One of the few non Medical Research related sources on the web with some information on CAMT is;
There appears to be no generic resource for CAMT patients on the web, and this is potentially due to the rariety of the disease.